← All stocks

Seres Therapeutics, Inc.

MCRB Net buying
CIK 0001609809 #4740 in the set updated 17 Sep 2026
Bought (120 mo)
$47.53M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$6.05M
$177.13K on a plan · $3.83M straight out of an exercise
Sold at will
$2.04M
22 of 106 sales
Net
+$41.48M
+$45.48M against sales at will

By person

22 insiders · 112 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Nutritional Health LTP Fund General Partner LLC entity
10% owner
$27.53M (2)
+$27.53M
6,201,513
$28.22M
AFEYAN NOUBAR
Director
$20.00M (2)
+$20.00M
2,750,135
$12.51M
Henn Matthew R
See Remarks
$2.53M (16) scheduled
−$2.53M
7,995
$36.38K
Pomerantz Roger
Director
$2.06M (16) scheduled
−$2.06M
213,976
$973.59K
+16.5%
Aunins John G.
Chief Technology Officer & EVP
$1.00M (11)
−$1.00M
105,250
$478.89K
−45.2%
Shaff Eric D.
Director
$116.26K (15) scheduled
−$116.26K
12,499
$56.87K
DesRosier Thomas
See Remarks
$92.85K (15) scheduled
−$92.85K
8,117
$36.93K
Ege David S.
See Remarks
$89.14K (6)
−$89.14K
77,575
$352.97K
Young Teresa L.
See Remarks
$60.64K (12) scheduled
−$60.64K
8,557
$38.93K
Trucksis Michele
See Remarks
$28.73K (1) scheduled
−$28.73K
4,893
$22.26K
von Moltke Lisa
See Remarks
$19.26K (7) scheduled
−$19.26K
39,875
$181.43K
COOK DAVID N
See Remarks
$19.15K (1) scheduled
−$19.15K
147,435
$670.83K
+7.9%
Chapman Marcus
See Remarks
$13.30K (1)
−$13.30K
8,600
$39.13K
Arkowitz David
Chief Financial Officer
$9.74K (2) scheduled
−$9.74K
182,442
$830.11K
+1,290%
Cloghessy Paula
See Remarks
$3.92K (1) scheduled
−$3.92K
45,684
$207.86K
+515.4%
Brady Kelly
See Remarks
$735.47 (2)
−$735.47
8,679
$39.49K
+2.8%
Flagship Ventures Fund IV General Partner LLC entity
10% owner
376,018
$1.71M
−95.5%
Kender Richard N
See Remarks
63,492
$288.89K
Biondi Paul
Director
47,619
$216.67K
Dere Willard H
Director
31,746
$144.44K
Zausner Meryl
Director
31,746
$144.44K
Berenson Stephen
Director
3,589
$16.33K

No percentages here. This company's share count has moved by a factor of 19.9 over the window, from 8,754,570 to 174,358,753 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Pomerantz Roger
24 Jan 2018
President and CEO
Exercised, kept
40,241
$0.71
$28.57K
Pomerantz Roger
18 Jul 2017
President and CEO
Exercised, kept
100,604
$0.71
$71.43K

What was left out

Form 4 filings counted 279
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 51
Sales straight out of an exercise 33
Sales at will 22
Transactions with no price 0
Shares from compensation/vesting 9,854,506
Sales filed before the plan box existed 20
History held since 20 Sep 2016